Mozobil

Generic name: Plerixafor

Usage of Mozobil

Mozobil works by helping your bone marrow release stem cells into your bloodstream so they can be collected and transplanted back into the body.

Mozobilis used in people with non-Hodgkin's lymphoma or multiple myeloma.

Mozobil may also be used for purposes not listed in this medication guide.

Mozobil side effects

Get emergency medical help if you have signs of an allergic reaction to Mozobil: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Tell your caregivers at once if you have a serious side effect such as:

easy bruising or bleeding, unusual weakness;

feeling like you might pass out; or

severe pain in your left upper stomach, spreading to your shoulder blade.

Common Mozobil side effects may include:

irritation where the medication was injected;

nausea, vomiting, diarrhea;

headache, dizziness;

tiredness; or

joint pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Mozobil

You should not be treated with Mozobil if you are allergic to plerixafor, or if you have leukemia.

If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you take Mozobil, tell your doctor if you have kidney disease.

Plerixafor may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using Mozobil and for at least 1 week after your last dose. Tell your doctor if you become pregnant.

You may need to have a negative pregnancy test before starting this treatment.

You should not breastfeed while receiving this medication.

How to use Mozobil

Usual Adult Dose for non-Hodgkin's Lymphoma:

Dosing Based on Actual Patient Body Weight: -83 kg or Less: 20 mg fixed dose or 0.24 mg/kg suBCutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis -Greater than 83 kg and Less than 160 kg: 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis Duration of Therapy: Up to 4 consecutive days Maximum Dose: 40 mg/day Comments: -The drug volume to be administered should be calculated using the following equation: 0.012 x actual patient body weight (kg) = administration dose (mL) -The dosing has been calculated based on actual patient body weight up to 175% of ideal body weight; dosing and treatment of patients weighing more than 175% of ideal body weight have not been investigated. -Granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg should be administered once daily in the morning for 4 consecutive days prior to the first dose of this drug and on each morning prior to apheresis. Use: Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Usual Adult Dose for Multiple Myeloma:

Dosing Based on Actual Patient Body Weight: -83 kg or Less: 20 mg fixed dose or 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis -Greater than 83 kg and Less than 160 kg: 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis Duration of Therapy: Up to 4 consecutive days Maximum Dose: 40 mg/day Comments: -The drug volume to be administered should be calculated using the following equation: 0.012 x actual patient body weight (kg) = administration dose (mL) -The dosing has been calculated based on actual patient body weight up to 175% of ideal body weight; dosing and treatment of patients weighing more than 175% of ideal body weight have not been investigated. -Granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg should be administered once daily in the morning for 4 consecutive days prior to the first dose of this drug and on each morning prior to apheresis. Use: Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Warnings

Do not receive Mozobil without telling your doctor if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment. You should not receive Mozobil if you are allergic to plerixafor, or if you have leukemia.

Before you receive this medicine, tell your doctor if you have kidney disease.

Mozobil is given as an injection in a hospital or clinic setting.

Before receiving Mozobil, you will be given another medication that will help your bone marrow produce stem cells and certain white blood cells that help support your immune system.

To be sure Mozobil is not causing harmful effects, your blood will need to be tested often

What other drugs will affect Mozobil

Other drugs may interact with plerixafor, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.